Xenon Pharmaceuticals, Inc.

Oncolytic viruses are, according to the Evaluate consensus, forecast to have the highest compound average growth rate (CAGR) of any technology over the next six years – with current estimates at 66%.

Biopharma companies work hard to stack their pipelines with promising candidates. But which candidates are the most promising? A recent report from Evaluate finds that the top three pipeline assets

In this edition of Scrip ’s M&A podcast, colleagues Joseph Haas, Kevin Grogan and Edwin Elmhirst highlight some of the companies they think are the most appealing takeout candidates for deep-pocketed

Licensing as an of external form of R&D and pipeline restocking for larger developers has increased in popularity hand-in-hand with the retraction of the M&A market in recent years. The ability to mit